| Website | immunetics.com |
| @Immunetics | |
| Category | BioTech |
| Phone | 617-896-9100 |
| Employees | |
| Founded | 1987 |
| TOTAL | $7.23M |
| FUNDING TOTAL | $7.23M |
| Grant, 5/11 | $2.4M |
| Grant, 5/11 Massachusetts Life Sciences Center | $500k |
| Venture Round, 8/12 | $629k |
| Grant, 9/12 National Institutes of Health | $3.7M |
Immunetics, Inc., a biotechnology company, researches and develops immunoassay and molecular probe kits and instruments for the diagnosis of infectious diseases. Its products include Miniblotter instrument system for western blot, spoligotyping, and various multi-probe membrane assays; cell adhesion flow chamber for cell-cell interaction studies; and C6 peptide Lyme ELISA, a synthetic peptide ELISA test for Lyme disease anthrax. The company’s products also include QuickELISA, a blood test for anthrax infection; and QualiCode western blot assays for diseases where diagnosis is challenging. In addition, it offers QuickELISA Anthrax-PA kit, an in vitro diagnostic test for the detection of antibodies to protective antigen of anthrax in human and animal samples; and BacTx Test for the bacterial contamination of platelets. The company sells its products through distributors in Belgium, Denmark, Norway, Finland, Sweden, France, Germany, Italy, the Netherlands, Switzerland, the United Kingdom, Canada, Honduras, Brazil, Ecuador, Venezuela, Australia, China, Korea, and Taiwan. Immunetics, Inc. was founded in 1987 and is based in Boston, Massachusetts.
